FTC Sides With Amneal Over Inhaler Patent Dispute With Teva

FTC’s Amicus Brief Called Teva’s Arguments “Unavailing And Inconsistent With The Statute”

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.